SILVER SPRING
Vabysmo label updated for macular edema treatment extension
- Sponsor
- Genentech $RHHBY
- Drug
- Vabysmo · faricimab-svoa
- Indication
- macular edema following retinal vein occlusion
FDA approved an updated label for Vabysmo (faricimab-svoa) to extend treatment duration for macular edema following retinal vein occlusion beyond six months.
What this means
Vabysmo is an eye injection that treats swelling in the retina by blocking two proteins that cause leaky blood vessels. The FDA updated its label to allow longer intervals between doses for patients with macular edema after retinal vein occlusion, potentially reducing the number of injections needed. This could mean fewer doctor visits for patients while maintaining vision protection.
Drug Watch — recent news on Vabysmo
- Early faricimab use linked to longer treatment durability - Ophthalmology Times Europe
- Vabysmo cuts injections while preserving vision in DME patients | ASRS 2026 - Managed Healthcare Executive
- ASRS 2026: initiating aflibercept 8 mg or faricimab earlier improves durability and anatomic outcomes in real-world practice - Ophthalmology Times Europe
- ASRS 2026: JADE trial shows OLN324 achieves faster retinal drying and durable response over faricimab in DME - Ophthalmology Times Europe
- Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting - Business Wire
Sponsor Watch — recent news on Genentech
- Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
- Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate
- Slate Medicines Appoints Mark W. Hahn to Board of Directors
- Roche Holding (SWX:ROP) Could Be 7% Undervalued On Pipeline Momentum
- Roche (SWX:ROG) Stock Could Trade At A Discount Despite Its 35% Run